Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 8/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 8/20 | 0.37 |
| ▸ | RELA | Q04206 | 8/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.30 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727016 | 0.95 | NFKB1 (0.38) | NFKB1NFKB2RELAAURKAPRKCB | |
| SCHEMBL1728278 | 0.84 | NFKB1 (0.39) | NFKB1NFKB2RELAAURKAPRKCB | |
| SCHEMBL1727021 | 0.81 | NFKB1 (0.37) | NFKB1NFKB2RELAAURKAPRKCB | |
| SCHEMBL29267639 | 0.76 | AURKA (0.50) | NFKB1NFKB2RELAAURKA | |
| SCHEMBL1726682 | 0.75 | NFKB1 (0.38) | NFKB1NFKB2RELAAURKAPRKCB | |
| SCHEMBL1727449 | 0.74 | NFKB1 (0.38) | NFKB1NFKB2RELAAURKAKDM4E | |
| SCHEMBL8115829 | 0.73 | AURKA (0.40) | NFKB1NFKB2RELAAURKA | |
| SCHEMBL14607263 | 0.72 | LSS (0.31) | — | |
| SCHEMBL1728345 | 0.72 | NFKB1 (0.37) | NFKB1NFKB2RELAAURKA | |
| SCHEMBL2019604 | 0.69 | CA12 (0.33) | NFKB1NFKB2RELAAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1609798-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-1609798-A9 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7566699-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1609798-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | NFKB1 3707/4885NFKB2 3464/4885RELA 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.